Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | REN | P00797 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27389168 | 0.88 | KISS1R (0.39) | BACE1CTSDKISS1RCYP3A4REN | |
| SCHEMBL30918360 | 0.88 | KISS1R (0.39) | BACE1CTSDKISS1RCYP3A4REN | |
| SCHEMBL27428793 | 0.88 | KISS1R (0.39) | BACE1CTSDKISS1RCYP3A4REN | |
| SCHEMBL30958913 | 0.88 | BACE1 (0.54) | BACE1CTSDKISS1R | |
| SCHEMBL27428888 | 0.88 | KISS1R (0.40) | BACE1CTSDKISS1RCYP3A4REN | |
| SCHEMBL29666893 | 0.88 | CYP3A4 (0.40) | BACE1KISS1RCYP3A4RENCTSL | |
| SCHEMBL30918318 | 0.87 | CTSL (0.53) | RENCTSLCTSB | |
| SCHEMBL29401136 | 0.86 | CYP3A4 (0.44) | CYP3A4CTSLCTSBGPR132 | |
| SCHEMBL30958909 | 0.84 | BACE1 (0.39) | BACE1CTSDKISS1RCYP3A4REN | |
| SCHEMBL29755521 | 0.83 | ACE (0.55) | CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | disclosed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | BACE1 1969/4885CTSD 1327/4885KISS1R 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.